REFRACTORY FOLLICULAR LYMPHOMA

This early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in patients whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose of the dru…

This study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…

This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…

This early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…

This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack two common proteins (CD19 and CD20) found on certain blood cancer cells. The therapy involves collecting a patient's own immune cells, modifying them in a lab to reco…

This study tested a daily pill called ibrutinib in 41 patients with follicular lymphoma, a type of blood cancer, that had returned or stopped responding to previous treatments. The main goal was to see how well the drug could shrink the cancer and control the disease. Researchers…

This early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for patients with certain types of lymphoma that have come back or stopped responding to previous treatments. The main goals are to find the safest dose and understand the side effects of …

This early-stage study is testing the safety and best dose of two drugs, ibrutinib and lenalidomide, when given together. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to previous treatments. The goal is to see if combining these drugs is s…

This early-stage study is testing the safety and best dose of a three-drug combination for patients with slow-growing non-Hodgkin's lymphoma that has returned or not responded to prior treatment. The drugs work together to help the immune system attack cancer cells and block a pr…

This study is testing a new three-drug combination to control B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see if adding a new immunotherapy drug (ALX148) to two existing drugs (rituximab and lenalidomide) helps patients whose cancer has returned or is newly d…

This study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…

This early-stage study is testing the safety and best dose of a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has come back or hasn't responded to other treatments. The goal is to see if this combination can help control the cancer. The stud…

This study aimed to see how well and how safe the pill tazemetostat was for adults whose follicular lymphoma, a type of blood cancer, had come back or stopped responding to treatment. It specifically focused on people whose cancer did not have a certain genetic change called an '…

This study is testing several new drug combinations to see which works best for adults with follicular lymphoma, a type of blood cancer, that has come back early or did not respond to their first round of treatment. Participants are assigned to receive one of three different trea…

This early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…

This study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…